Guinea Pig Cytomegalovirus: Veterinary Reference
Overview and Taxonomy of Guinea Pig Cytomegalovirus (GPCMV)
Introduction and Virological Significance
Guinea pig cytomegalovirus (GPCMV) represents a highly relevant and experimentally tractable model for the study of human cytomegalovirus (HCMV) pathogenesis, particularly in the context of congenital infection and vaccine development. As a member of the Betaherpesvirinae subfamily within the Herpesviridae family, GPCMV shares profound biological and genomic parallels with HCMV, making the guinea pig (Cavia porcellus) an indispensable small animal model for translational research. The utility of this model is underscored by the fact that, unlike murine cytomegalovirus (MCMV), GPCMV is capable of crossing the placenta and causing congenital infection in a manner that closely recapitulates human disease [1]. This unique attribute positions GPCMV as a critical tool for investigating mechanisms of vertical transmission, immune evasion, and the efficacy of experimental vaccines and therapeutics. The World Health Organization (WHO) has long recognized congenital HCMV as a leading infectious cause of birth defects and sensorineural hearing loss globally, and the GPCMV model provides a direct, in vivo platform to address this pressing public health concern.
Taxonomic Classification and Phylogenetic Context
GPCMV is formally classified within the order Herpesvirales, family Herpesviridae, subfamily Betaherpesvirinae, and genus Cytomegalovirus. The species is designated as Caviid betaherpesvirus 2, reflecting its host specificity for the guinea pig. This taxonomic placement is supported by morphological, genomic, and biological characteristics. Electron microscopy of GPCMV virions reveals the canonical herpesvirus architecture: an icosahedral capsid approximately 100–110 nm in diameter, surrounded by a tegument layer and a lipid envelope studded with viral glycoproteins [1]. The virus exhibits a relatively narrow host range, a hallmark of the betaherpesviruses, and establishes lifelong latency with periodic reactivation, particularly under conditions of immunosuppression.
Phylogenetically, GPCMV is more closely related to HCMV than to rodent cytomegaloviruses such as MCMV or rat cytomegalovirus (RCMV). This closer evolutionary relationship is reflected in the conservation of gene content and genomic organization, particularly within the central core region of the genome that encodes essential replication and structural proteins. However, significant divergence exists in the terminal repeat regions, which harbor genes involved in host immune modulation and tropism. The availability of multiple GPCMV strains, including the prototypical 22122 strain and the more recently isolated CIDMTR strain, has enabled detailed comparative genomic analyses that illuminate the evolutionary dynamics and functional plasticity of the viral genome [1, 2].
Genomic Architecture and Strain Diversity
The GPCMV genome is a linear double-stranded DNA molecule, approximately 232,778 base pairs in length for the CIDMTR strain, making it one of the larger genomes among the betaherpesviruses [1, 2]. The genome is organized into unique long (UL) and unique short (US) segments, flanked by terminal and internal repeat sequences, a structure typical of the Herpesviridae. Sequencing of the CIDMTR strain using Illumina and PacBio platforms revealed a high degree of overall conservation with the reference 22122 strain, but also identified regions of substantial sequence divergence that are of considerable biological interest [2].
One of the most striking findings from the genomic characterization of the CIDMTR strain is the presence of novel open reading frames (ORFs) not found in the 22122 reference strain. Notably, an additional major histocompatibility complex (MHC) class I homolog was identified near the right genome terminus [1]. This is a critical observation because MHC class I homologs are well-established immune evasion molecules in HCMV, where they interfere with natural killer (NK) cell recognition and cytotoxic T lymphocyte (CTL) responses. The presence of a strain-specific MHC class I homolog in CIDMTR suggests that different GPCMV isolates may have evolved distinct strategies for subverting the host immune response, a phenomenon that has profound implications for modeling reinfection and vaccine-induced immunity. The ability of the CIDMTR strain to disseminate in immunocompromised guinea pigs and, critically, to cause congenital transmission in dams previously infected with the salivary gland-adapted 22122 strain, demonstrates that pre-existing immunity is insufficient to prevent reinfection and vertical transmission [1]. This directly mirrors the clinical challenge observed in human populations, where HCMV-seropositive women can still experience reinfection with new strains and transmit the virus to their fetuses.
Biological Mechanisms of Pathogenesis and Immune Evasion
The pathogenesis of GPCMV is intimately linked to its ability to manipulate the host immune system. Following primary infection, the virus establishes a productive infection in a variety of cell types, including epithelial cells, endothelial cells, fibroblasts, and macrophages. The salivary gland is a major site of viral replication and persistence, and salivary gland-adapted strains, such as the 22122 strain, are particularly virulent and have been the workhorse of experimental infection models for decades [1]. The virus disseminates hematogenously, likely within infected leukocytes, and can cross the placental barrier to infect the developing fetus.
The immune evasion strategies employed by GPCMV are multifaceted and include the modulation of NK cell responses through MHC class I homologs, interference with interferon signaling, and the downregulation of antigen presentation pathways. The discovery of a novel MHC class I homolog in the CIDMTR strain expands the repertoire of known immune evasion genes and provides a molecular explanation for the ability of this strain to reinfect immune hosts [1, 2]. From a mechanistic standpoint, these viral MHC class I homologs are thought to act as decoys, engaging inhibitory receptors on NK cells and thereby preventing the destruction of infected cells. This is a sophisticated evolutionary adaptation that allows the virus to persist in the face of a robust host immune response.
The guinea pig host itself has been extensively characterized in terms of its normal physiological and immunological parameters, which is essential for interpreting experimental outcomes in GPCMV research. For example, reference intervals for hematological and biochemical parameters have been established for the Dunkin Hartley strain, the most commonly used guinea pig in biomedical research [4]. Age- and sex-associated differences in white blood cell counts, including heterophils (the guinea pig equivalent of neutrophils), lymphocytes, and monocytes, have been documented, and these data are critical for designing experiments that assess the impact of GPCMV infection on the host hematopoietic system [4]. Similarly, coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen levels, have been validated for strain 13/N guinea pigs, which are used in hemorrhagic fever virus research but also serve as a model for understanding the coagulopathies that can accompany severe viral infections [3]. The availability of these reference data enhances the rigor and reproducibility of GPCMV studies.
The Guinea Pig as a Model for Congenital HCMV Infection
The guinea pig is uniquely suited among small laboratory animals for modeling congenital HCMV infection due to the structure of its placenta. Unlike mice and rats, which have a hemotrichorial placenta, guinea pigs possess a hemomonochorial placenta that is structurally and functionally similar to the human placenta. This anatomical feature is a critical determinant of the ability of GPCMV to cross the maternal-fetal interface, a process that is inefficient or absent in murine models. The CIDMTR strain has been shown to be particularly adept at congenital transmission, even in the presence of pre-existing immunity, making it an invaluable tool for testing vaccines and immunotherapies aimed at preventing vertical transmission [1].
The use of guinea pigs in vaccine potency testing is not limited to GPCMV research. The species has been validated as a surrogate model for evaluating the potency of vaccines against other pathogens, including Infectious Bovine Rhinotracheitis (IBR) virus and rabies virus [5, 6]. In the IBR model, a statistically validated guinea pig potency test demonstrated a dose-response relationship to the BoHV-1 antigen concentration and was able to discriminate between vaccines of differing potency with high repeatability and reproducibility [5]. Concordance analysis showed almost perfect agreement between the guinea pig model and the target species (cattle) for antibody titers measured by ELISA [5]. Similarly, the guinea pig potency test for rabies vaccines has been used as an official standard in Japan, and the results correlate well with the NIH potency test and with protection in dogs [6]. These examples underscore the broader utility of the guinea pig as a predictive model for vaccine efficacy and highlight the robustness of the species for immunological studies.
Epidemiological Context and Diagnostic Considerations
GPCMV is a species-specific pathogen and is not known to be zoonotic. However, its importance lies in its role as a model for a major human pathogen. The epidemiology of GPCMV in laboratory guinea pig colonies is not well-documented, but it is likely that the virus is enzootic in many conventional colonies, with most animals becoming infected early in life. Subclinical infections are common, and stress or immunosuppression can lead to reactivation and shedding. This has practical implications for veterinary care and colony management, as intercurrent GPCMV infection can confound experimental results, particularly in studies involving immunomodulation or reproductive biology.
Diagnosis of GPCMV infection relies on a combination of serological and molecular methods. Enzyme-linked immunosorbent assays (ELISAs) can detect antibodies against viral antigens, while polymerase chain reaction (PCR) assays targeting conserved regions of the genome, such as the DNA polymerase gene, are used for direct detection of viral DNA in tissues, blood, or saliva. Electron microscopy remains a valuable tool for visualizing virions in clinical samples or cell culture supernatants [1]. The availability of complete genome sequences for both the 22122 and CIDMTR strains facilitates the design of strain-specific PCR assays, which are essential for distinguishing between primary infection and reinfection in experimental settings [1, 2].
From a One Health perspective, the GPCMV model contributes to the global effort to reduce the burden of congenital HCMV infection, a condition that the WHO and the US Centers for Disease Control and Prevention (CDC) have identified as a priority for vaccine development. The insights gained from studying GPCMV pathogenesis, immune evasion, and vertical transmission are directly translatable to the design of HCMV vaccines and antiviral strategies. The World Organisation for Animal Health (WOAH) does not list GPCMV as a notifiable disease, but the species is recognized as a valuable experimental model in veterinary and medical research. The continued characterization of GPCMV strains, including the identification of novel immune evasion genes, will be essential for advancing our understanding of betaherpesvirus biology and for developing effective interventions against HCMV.
Molecular Pathogenesis and Genetic Diversity of GPCMV Strains
The guinea pig cytomegalovirus (GPCMV) model occupies a uniquely indispensable niche within the pantheon of cytomegalovirus research, particularly for the study of congenital infection and the perplexing phenomenon of reinfection in hosts with pre-existing immunity. For decades, the field operated with a single, historically isolated viral reference, the 22122 strain, first recovered in 1957, which served as the cornerstone for virtually all mechanistic and vaccine-related investigations. The profound limitations of this singular genetic lens became increasingly apparent as researchers sought to model the complexities of human cytomegalovirus (HCMV) epidemiology, where reinfection with distinct viral strains is a documented contributor to vertical transmission, even in seropositive women. The identification and comprehensive characterization of the CIDMTR strain represent a paradigm-shifting advancement, providing the first genuine opportunity to dissect the molecular determinants of strain-specific pathogenesis, immune evasion, and intra-host competition within a controlled small animal system [1, 2, 7].
The genomic architecture of GPCMV, as revealed through high-throughput sequencing of both the 22122 and CIDMTR strains, exhibits the canonical features of a betaherpesvirus, with a large double-stranded DNA genome exceeding 230,000 base pairs. For the CIDMTR strain, Illumina and PacBio sequencing resolved a genome of 232,778 nucleotides, confirming its morphological classification within the Herpesvirinae subfamily while simultaneously exposing regions of substantial sequence divergence from the 22122 reference [1, 2]. The most striking genetic disparity identified in the CIDMTR strain is the presence of a novel open reading frame (ORF) encoding an additional major histocompatibility complex (MHC) Class I homolog, located in proximity to the right genome terminus, a genomic territory frequently associated with immune modulation functions in cytomegaloviruses [1]. This finding is of paramount molecular and pathogenic significance. The MHC Class I homologs encoded by cytomegaloviruses are not inert structural mimics; rather, they are sophisticated molecular decoys that subvert the host’s adaptive immune surveillance. In HCMV, the UL18 and UL142 gene products, among others, function to bind host β2-microglobulin and interact with natural killer (NK) cell receptors, effectively cloaking infected cells from NK-mediated lysis. The acquisition of an additional, strain-specific MHC Class I homolog in CIDMTR suggests a divergent evolutionary strategy for immune evasion, potentially conferring upon this isolate a distinct capacity to resist innate immune clearance mechanisms that may have been selected for in the immunocompromised or partially immune host environment from which it was isolated.
The biological relevance of this genetic diversity is not merely theoretical; it is demonstrated with striking clarity in experimental infection models. The CIDMTR strain, unlike the laboratory-adapted 22122 strain, possesses the demonstrated capacity for dissemination in immunocompromised guinea pigs, a phenotype that underscores its enhanced pathogenic potential in hosts with compromised immune defenses [1]. More critically, CIDMTR is capable of establishing congenital transmission in guinea pig dams that were previously infected with the salivary gland-adapted 22122 strain and were therefore seropositive and presumably immune [1]. This experimental observation directly mirrors the clinical conundrum of HCMV reinfection in seropositive pregnant women, a scenario that the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have long recognized as a significant contributor to the global burden of congenital CMV disease. The molecular basis for this reinfection capability is likely multifactorial, involving the aforementioned immune evasion genes, but also potentially including polymorphisms in glycoprotein complexes critical for viral entry (gB, gH/gL/gO) and cell tropism. The presence of strain-specific ORFs that are not found in the 22122 genome, as annotated in the CIDMTR sequence, provides a rich catalog of candidate genes that may mediate these phenotypic differences [2]. These unique genetic elements likely encode proteins that modulate the host innate immune response, including interference with interferon signaling, chemokine sequestration, or the subversion of NK cell activity, thereby enabling the virus to overcome the immunological barrier established by prior infection with a heterologous strain.
Beyond these discrete, high-impact genetic differences, the broader comparative genomics of the two GPCMV isolates reveals a mosaic of conservation and divergence. While the core replication machinery and structural components are largely conserved, as is typical for herpesviruses, the terminal and sub-terminal regions of the genome, often referred to as the "variable regions", harbor the majority of strain-specific sequence variation. This genetic plasticity is a hallmark of cytomegaloviruses, driven by selective pressures from the host immune system and the need for host adaptation. In the context of GPCMV, this diversity provides the raw material for investigating the molecular correlates of virulence and transmissibility. The CIDMTR strain, isolated from a different geographic and temporal context than the 22122 strain, likely represents a viral lineage that has evolved in response to distinct host pressures, potentially including differing MHC haplotypes or endemic co-infections. The regions of substantial sequence divergence observed between the strains are therefore not random noise but are likely to encode determinants of host range, tissue tropism, and the capacity for horizontal and vertical transmission. Understanding the functional consequences of these differences is critical for interpreting data derived from vaccine challenge studies and for rationally designing next-generation vaccines or therapeutics that must be effective against a spectrum of viral genotypes, a consideration that mirrors the global genetic diversity of HCMV itself.
The implications of this genetic diversity for the GPCMV model of congenital CMV transmission and vaccine development are profound. The availability of two genetically distinct, biologically characterized strains, the well-studied 22122 and the newly isolated CIDMTR, now enables controlled in vivo head-to-head comparisons of virulence, replication kinetics, and immunogenicity. Researchers can now probe whether specific genetic elements, such as the novel MHC Class I homolog in CIDMTR, directly confer a fitness advantage in the context of maternal-fetal transmission or in evasion of vaccine-induced antibody responses. This dual-strain system is directly analogous to the HCMV landscape, where diverse clinical isolates display variable pathogenic properties and susceptibilities to neutralization. Furthermore, the CIDMTR strain’s capacity to reinfect immune animals provides a validated platform for testing therapeutic interventions, including monoclonal antibodies, antivirals, and vaccines, designed to prevent secondary infection and vertical transmission, a key regulatory endpoint sought by agencies such as the WHO. The molecular dissection of these strains, through the use of recombinant viruses, targeted gene knockouts, and heterologous expression studies, will be essential to assigning function to the annotated strain-specific ORFs and to unraveling the intricate host-pathogen interactions that govern the pathogenesis of congenital CMV. The study of GPCMV genetic diversity, therefore, is not an esoteric pursuit; it is a fundamental prerequisite for the translational development of interventions aimed at one of the most common infectious causes of long-term neurodevelopmental disability in children globally.
Epidemiology and Transmission Dynamics of GPCMV in Cavia porcellus
Guinea pig cytomegalovirus (GPCMV), a member of the Betaherpesvirinae subfamily, represents a critical model for understanding human cytomegalovirus (HCMV) pathogenesis, particularly congenital infection and the phenomenon of reinfection in seroimmune hosts. The epidemiology and transmission dynamics of GPCMV within Cavia porcellus populations are shaped by a complex interplay of viral strain diversity, host immune status, environmental factors, and the unique reproductive physiology of the guinea pig. Unlike many rodent models, the guinea pig shares with humans a hemomonochorial placentation, making it the only small animal model capable of supporting transplacental viral transmission, a feature that places GPCMV at the forefront of congenital infection research. Understanding the natural history of GPCMV in its native host is therefore not merely an academic exercise but a translational imperative, informing vaccine development and therapeutic strategies against HCMV, which remains the leading infectious cause of birth defects worldwide according to the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).
Prevalence and Host Susceptibility in Laboratory and Pet Populations
GPCMV is considered ubiquitous in conventionally housed guinea pig colonies, with seroprevalence rates approaching 100% in many closed breeding facilities. This near-universal exposure pattern mirrors that of HCMV in human populations, where seropositivity often exceeds 90% in developing regions. However, the epidemiological landscape is shifting as guinea pigs gain popularity as companion animals [7]. While systematic serosurveys of pet guinea pigs are lacking, the fragmented nature of the pet population, with animals originating from diverse breeders, pet stores, and rescues, likely results in a more heterogeneous prevalence pattern compared to laboratory settings. Young animals are particularly susceptible to primary infection, and vertical transmission from dam to offspring represents a significant mechanism for viral persistence within populations [1]. Notably, the use of specific-pathogen-free (SPF) barrier facilities has created a bifurcation in GPCMV epidemiology: SPF colonies remain seronegative and are highly susceptible to experimental infection, while conventional colonies maintain enzootic stability through lifelong latency and intermittent reactivation.
Host factors such as age, sex, and genetic background modulate susceptibility and transmission efficiency. Hematological studies in Dunkin Hartley guinea pigs have documented significant age- and sex-related variations in leukocyte populations, including heterophils, lymphocytes, and Foa-Kurloff cells [4]. Given that GPCMV, like all cytomegaloviruses, establishes latency in myeloid lineage cells, age-associated shifts in these populations could influence viral reactivation dynamics and subsequent shedding. For instance, the observed increase in heterophil counts with age [4] may correlate with altered innate immune responses during viral reactivation. Strain-specific differences are also relevant: the CIDMTR strain, a recently characterized isolate, demonstrated robust dissemination in immune-compromised animals [1, 2], suggesting that host immunocompetence is a critical determinant of viral spread. Immune-compromised states, whether induced experimentally or occurring naturally through age, malnutrition, or coinfection, can transform a typically latent infection into a lytic, highly transmissible state. This phenomenon is particularly relevant in the context of pet guinea pigs, which may present with concurrent diseases such as sporotrichosis or gastrointestinal disorders [7, 10], potentially altering their susceptibility to GPCMV reactivation and transmission.
Strain Diversity and the Implications for Reinfection Epidemiology
The epidemiology of GPCMV has been historically constrained by the availability of only a single reference strain, the 22122 strain isolated in 1957. The recent isolation and genomic characterization of the CIDMTR strain has fundamentally reshaped our understanding of GPCMV diversity and its implications for transmission dynamics [1, 2]. Whole-genome sequencing revealed a 232,778-nucleotide genome that is largely syntenic with strain 22122 but harbors regions of substantial divergence, including novel open reading frames (ORFs) encoding an additional MHC Class I homolog near the right genome terminus [1, 2]. This immune evasion gene is of particular epidemiological significance: MHC Class I homologs are known to interfere with natural killer cell recognition, potentially enhancing the capacity of the CIDMTR strain to establish infection in the face of pre-existing immunity. Indeed, the CIDMTR strain was capable of congenital transmission in GPCMV-immune dams previously infected with the salivary gland-adapted 22122 strain [1]. This finding directly models the clinical conundrum of HCMV reinfection in seropositive women, a phenomenon increasingly recognized as a major contributor to congenital HCMV transmission. The WHO has identified congenital CMV as a priority for vaccine development, and the GPCMV reinfection model provides a uniquely translatable platform for evaluating candidate vaccines.
The existence of multiple GPCMV strains with distinct genomic architectures raises critical questions about the transmission dynamics of mixed infections within guinea pig populations. It is plausible that, as with HCMV, multiple strains can cocirculate within a single colony, with strain-specific recombination events driving ongoing viral evolution. The CIDMTR strain’s ability to overcome immune barriers established by prior 22122 infection suggests that strain-specific neutralizing antibody responses may be insufficient to block heterologous strain transmission. This has profound implications for vaccine design: a monovalent vaccine based on a single GPCMV strain may not provide broad protection against genetically divergent circulating strains. The World Organisation for Animal Health (WOAH) has long recognized the importance of strain diversity in the epidemiology of viral diseases of veterinary significance, and GPCMV serves as a powerful model for this principle. Future epidemiological surveillance of GPCMV in both laboratory and pet populations should incorporate molecular typing methods, such as targeted sequencing of the divergent MHC Class I homolog region, to map strain distribution and track transmission chains.
Horizonal and Vertical Transmission Pathways
GPCMV transmission occurs via both horizontal and vertical routes, mirroring the transmission biology of HCMV. Horizontal transmission is primarily mediated through direct contact with infectious secretions, particularly saliva and urine. Infected guinea pigs shed virus intermittently from salivary glands, with viral titers peaking during primary infection and during episodes of reactivation. The guinea pig’s natural behaviors, communal nesting, allogrooming, and shared food and water sources, facilitate efficient oro-nasal transmission within groups. In laboratory settings, the use of wire-bottom cages and individual ventilation may reduce fomite-mediated spread, but direct contact transmission remains difficult to control in breeding colonies. The latency-reactivation cycle is central to GPCMV persistence: once infected, an animal carries the virus for life, with reactivation triggered by stress, immunosuppression, or inflammation. Studies of hemorrhagic fever virus models have utilized inbred Strain 13/N guinea pigs [3], a strain that may exhibit distinct reactivation kinetics compared to outbred Dunkin Hartley animals, further complicating cross-colony transmission predictions.
Vertical transmission from dam to offspring is the most consequential pathway from a public health and vaccine development perspective. The guinea pig’s hemomonochorial placenta is structurally analogous to the human placenta, allowing GPCMV to cross the placental barrier and infect the fetus [1]. In the CIDMTR strain model, congenital transmission occurred even in dams with pre-existing immunity from prior 22122 infection [1], underscoring the potency of this transmission route. The timing of maternal infection relative to gestation likely influences transmission efficiency, analogous to HCMV where primary infection in early pregnancy carries the highest risk of severe fetal sequelae. Unlike mice, guinea pigs deliver precocial young that are developmentally advanced, and the impact of congenital GPCMV on fetal outcomes, including growth restriction, neurodevelopmental deficits, and sensorineural hearing loss, can be assessed with translational relevance. Salivary gland-adapted strains, such as the 22122 strain passaged through guinea pig salivary glands, exhibit enhanced tropism for placental and fetal tissues, suggesting that tissue adaptation during serial passage can alter transmission kinetics.
The potential for iatrogenic transmission in veterinary settings should not be overlooked. Guinea pigs are frequently anesthetized for diagnostic procedures [9], and contaminated equipment, such as endotracheal tubes or injection needles, could theoretically serve as fomites. However, GPCMV is enveloped and relatively labile in the environment, limiting indirect transmission compared to non-enveloped viruses. The detection of OXA-48 carbapenemase-producing Enterobacteriaceae in a guinea pig from a veterinary clinic [11] highlights the reality of nosocomial pathogen transmission in exotic animal medicine, underscoring the need for rigorous infection control protocols that would also apply to GPCMV management. While GPCMV is not zoonotic, it is strictly species-specific to Cavia porcellus, its epidemiological parallels to HCMV make it a valuable sentinel for understanding betaherpesvirus transmission dynamics in general.
Environmental and Ecological Determinants
The ecological niche of Cavia porcellus, whether as a laboratory animal, a pet, or in rare cases, a free-ranging feral animal, profoundly influences GPCMV transmission dynamics. In laboratory facilities, environmental variables such as cage density, ventilation rates, and sanitation frequency directly impact viral spread. High-density housing, common in breeding colonies, facilitates rapid horizontal transmission and the maintenance of enzootic infection. Conversely, the introduction of a seronegative animal into an endemically infected colony can precipitate outbreaks of primary infection, with widespread shedding and potential for vertical transmission if pregnant dams are exposed. The use of barrier housing, autoclaved bedding, and individually ventilated cages can interrupt transmission chains, but these measures are costly and often impractical in research settings with limited resources.
Pet guinea pigs face different epidemiological pressures. They are frequently housed singly or in small groups, reducing opportunities for horizontal transmission. However, the pet trade introduces animals from diverse geographic and genetic backgrounds, increasing the likelihood of introducing novel GPCMV strains into naive populations. Additionally, the stress of transport, changes in diet, and concurrent illness, such as the fungal infections increasingly reported in pet guinea pigs [7], may trigger viral reactivation in latently infected animals, leading to shedding that poses a risk to cohoused conspecifics. The Food and Agriculture Organization (FAO) has emphasized the importance of understanding disease dynamics in companion animals within the One Health framework, and while GPCMV does not cross species barriers, the management of this infection in pet populations can inform broader principles of viral transmission in captive environments.
Seasonal or environmental temperature fluctuations may also play a role, though data specific to GPCMV are lacking. In other herpesviruses, stress-induced glucocorticoid release has been linked to reactivation, and the hypothalamic-pituitary-adrenal axis of guinea pigs is responsive to environmental stressors. Laboratory guinea pigs are typically housed under constant temperature and photoperiod, but pet animals may experience greater environmental variability. The cerebellum of the guinea pig has been extensively studied using stereological methods [8], and while these studies focus on neuroanatomy rather than virology, they establish baseline parameters for future investigations into GPCMV-induced neuropathology and its correlation with transmission risk.
Modeling Transmission Dynamics for Vaccine and Therapeutic Development
The epidemiological features of GPCMV make it an indispensable tool for preclinical evaluation of interventions aimed at preventing congenital HCMV transmission. The availability of multiple strains, including the well-characterized 22122 strain and the newly isolated CIDMTR strain, allows researchers to model primary infection, reinfection, and vaccine breakthrough in a controlled setting. Vaccine potency testing in guinea pigs has been validated for other viral pathogens, including bovine herpesvirus 1 (BoHV-1) and rabies virus [5, 6], establishing a regulatory precedent for using the guinea pig as a surrogate species. For GPCMV, the ability to measure vertical transmission efficiency following vaccination is a key endpoint, mirroring the WHO’s priority of preventing in utero HCMV transmission.
Mathematical modeling of GPCMV transmission, analogous to the in silico approaches used for bovine tuberculosis epidemiology [12], could further refine our understanding of outbreak dynamics and intervention strategies. Parameters such as the basic reproduction number (R₀), latency period, and reactivation rate could be estimated from controlled transmission studies and used to predict the impact of vaccination or antiviral therapy on population-level transmission. Such models would be particularly valuable for designing management strategies for SPF colonies that may become inadvertently exposed, as well as for predicting the risk of congenital infection in breeding facilities. The WHO’s global burden of disease estimates for congenital CMV underscore the urgency of these translational efforts, and the GPCMV model remains the most biologically relevant small animal system for addressing this public health challenge.
Clinical Manifestations and Pathological Findings of GPCMV Infection
The clinical spectrum of guinea pig cytomegalovirus (GPCMV) infection encompasses a remarkable breadth, ranging from clinically inapparent latency to fulminant, life-threatening disease. Understanding this continuum is paramount for the veterinary practitioner, particularly as guinea pigs transition from being almost exclusively laboratory models to increasingly popular companion animals [13]. The hallmark of GPCMV, like other betaherpesviruses, is its capacity for lifelong persistence following primary infection, punctuated by the potential for reactivation, especially under conditions of immunosuppression. The clinical and pathological features are inextricably linked to the host’s immune status, the viral strain involved, and the ontogenic stage at which infection occurs, with congenital infection representing the most severe and consequential manifestation.
Acute Infection in the Immunocompetent Host
In immunocompetent adult guinea pigs, primary GPCMV infection is typically subclinical or produces only mild, transient signs that may escape clinical detection. Experimental studies utilizing reference strains, such as the prototypical 22122 strain, have historically demonstrated a highly attenuated phenotype in immunologically intact animals. The infection is often confined to the salivary glands, a classic predilection site for cytomegaloviruses, where viral replication can persist for weeks to months without eliciting overt systemic illness. The virus establishes latency in various tissues, and healthy seropositive animals serve as reservoirs for horizontal transmission, primarily through contaminated saliva and urine. The specific clinical signs, when present, are often nonspecific and may include transient lethargy, mild inappetence, or subtle weight loss. Conjunctivitis and rhinitis with serous ocular and nasal discharges have been anecdotally reported, though these are difficult to attribute solely to GPCMV in a clinical setting where co-infections are common.
The isolation and characterization of the newer CIDMTR strain have refined our understanding of GPCMV pathogenesis [1, 2]. While still capable of establishing persistent infection, this strain demonstrates a broader cellular tropism and enhanced replicative capacity in certain contexts. Critically, the CIDMTR strain was shown to disseminate systemically in immunocompromised guinea pigs, a finding that underscores the critical role of T-cell-mediated immunity in controlling viral spread [1]. In the immunocompetent host, the CIDMTR strain likely remains largely controlled, but its genetic divergence from the 22122 strain, particularly in the region encoding immune modulation gene products, including an additional MHC Class I homolog, suggests a refined capacity for immune evasion that may subtly alter the trajectory of acute infection [1, 2]. The clinical relevance of this for the average pet guinea pig, which may harbor concurrent subclinical conditions or age-related immune senescence, remains an important area of investigation.
Clinical Manifestations in Immunocompromised and Neonatal Animals
The most profound clinical disease associated with GPCMV occurs in hosts with compromised immune function. This is most dramatically illustrated in the neonatal guinea pig, which serves as a model for congenital human CMV infection. Pups infected in utero or shortly after birth may develop a syndrome characterized by failure to thrive, stunted growth, hepatitis, pneumonitis, and a spectrum of neurologic deficits. Clinically, these animals present with poor body condition, rough hair coats, weakness, and a palpable hepatosplenomegaly. Jaundice may be evident in cases of severe hepatitis. Respiratory distress, characterized by tachypnea, dyspnea, and abnormal lung sounds, reflects viral interstitial pneumonia.
In adult guinea pigs subjected to experimental immunosuppression, for example, through cyclophosphamide administration or whole-body irradiation, infection with a virulent GPCMV strain like CIDMTR leads to a rapid and often fatal disseminated disease [1]. The clinical picture is one of acute systemic illness: profound lethargy, anorexia, rapid weight loss, pyrexia or hypothermia (depending on the stage), and signs referable to multi-organ failure. As the disease progresses, animals may develop petechial or ecchymotic hemorrhages due to viral-induced thrombocytopenia and consumptive coagulopathy. Reference intervals for coagulation parameters in guinea pigs, including prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen, have been established and are critical for assessing hemostatic function in these cases [3]. Disseminated intravascular coagulation (DIC), characterized by prolonged clotting times, thrombocytopenia, and elevated D-dimer levels, can be a terminal event.
Pathological Findings: Gross and Histopathological Correlates
The pathology of GPCMV infection is dominated by the hallmark cytomegalic inclusion-bearing cell, an enlarged cell (typically 25-40 μm in diameter) containing a prominent intranuclear basophilic inclusion that displaces the chromatin to the nuclear membrane, creating an "owl's eye" appearance. Eosinophilic intracytoplasmic inclusions may also be present. These cells are the histopathologic signature of active viral replication.
Salivary Glands: The salivary glands, particularly the submandibular and parotid glands, are the most consistently affected tissues. Grossly, they may appear normal or slightly enlarged. Histologically, there is a multifocal to diffuse interstitial inflammation composed of lymphocytes, plasma cells, and histiocytes. Cytomegalic inclusion bodies are readily identified within the epithelial cells of the intralobular and interlobular ducts. Acinar cells are less frequently involved. This sialadenitis is generally self-limiting in immunocompetent animals but can be severe and necrotizing in neonates or immunosuppressed individuals.
Lungs: Interstitial pneumonia is a common finding in severe disseminated disease, particularly in neonates and immunocompromised adults. Grossly, the lungs are firm, edematous, and fail to collapse; they may exhibit a mottled tan-red appearance. Histopathological examination reveals thickening of the alveolar septa due to the infiltration of mononuclear cells, type II pneumocyte hyperplasia, and the presence of cytomegalic cells within alveolar epithelial cells and endothelial cells. Hyaline membranes may line alveolar spaces in severe cases, indicative of acute lung injury. Alveoli may also contain proteinaceous fluid, fibrin, and hemosiderin-laden macrophages.
Liver: Hepatitis is a consistent feature of congenital and disseminated GPCMV infection. The liver may be enlarged and friable, with an accentuated lobular pattern. Microscopically, there are multifocal to coalescing areas of hepatocellular necrosis, often associated with an infiltrate of neutrophils and mononuclear cells. Cytomegalic inclusion bodies are found within hepatocytes, Kupffer cells, and biliary epithelium. Intranuclear inclusions are commonly observed in hepatocytes adjacent to necrotic foci. Cholestasis may be present in severe cases.
Kidneys: Renal involvement is common. Grossly, the kidneys may appear normal or slightly pale. Histologically, there is a multifocal interstitial nephritis with lymphocytic and plasma cell infiltration. Cytomegalic inclusions are identified within tubular epithelial cells, particularly in the distal convoluted tubules and collecting ducts. Glomeruli are typically spared, although periglomerular inflammation can be seen. Viral antigen may also be present in mesangial cells.
Brain: In congenital infection, neurologic disease can manifest as meningoencephalitis, ventriculitis, and microcephaly. Grossly, the brain may appear grossly normal or show subtle ventriculomegaly. Histopathological examination is critical. Characteristic findings include perivascular cuffing with mononuclear cells, microglial nodules, and focal areas of necrosis. Cytomegalic inclusion bodies are found within neurons, astrocytes, and ependymal cells. The cerebellum is particularly vulnerable. Understanding the normal morphometric parameters of the guinea pig cerebellum, such as the volumes of the granular and molecular layers, and the total number and volume of Purkinje cells, provides a crucial baseline for interpreting pathological alterations induced by congenital CMV, which can include Purkinje cell loss, disorganization of the granular layer, and cerebellar hypoplasia [8].
Other Tissues: Disseminated infection can involve virtually any organ system. Inclusion bodies and inflammation can be found in the pancreas, adrenal glands, gastrointestinal tract (particularly the colon), spleen, lymph nodes, and bone marrow. Splenomegaly with white pulp hyperplasia and lymphoid depletion can occur concurrently. In the placenta, characteristic cytomegalic cells are evident in trophoblasts and endothelial cells, providing the route for vertical transmission to the fetus.
Atypical and Differential Diagnostic Considerations
The clinical and pathological findings of GPCMV infection must be differentiated from other infectious and non-infectious diseases of guinea pigs. Bacterial infections, such as those caused by Streptococcus pneumoniae, Bordetella bronchiseptica, or Klebsiella pneumoniae, can produce similar respiratory signs and should be ruled out through culture and PCR. Gastric dilatation-volvulus (GDV) is a critical differential for acute abdominal distension and shock, but GDV lacks the multi-organ involvement and characteristic histopathology of disseminated CMV [10]. Fungal diseases, like sporotrichosis caused by Sporothrix spp., can present with cutaneous lesions and systemic signs in immunocompromised animals, but these would not produce the classic "owl's eye" inclusions on histopathology [7]. The presence of cytomegalic cells in a tissue sample is highly suggestive of CMV infection, but immunohistochemistry or in situ hybridization targeting GPCMV-specific antigens or nucleic acids is required for definitive confirmation.
Immunopathology and Viral Evasion
The pathological damage in GPCMV infection is a composite of direct viral cytopathic effect and the host's inflammatory-immune response. The virus has evolved sophisticated mechanisms to subvert the host's immune surveillance, including the encoding of MHC Class I homologs that are hypothesized to interfere with natural killer (NK) cell detection and antigen presentation [1, 2]. This immune modulation allows the virus to establish persistent infection and reactivate when host defenses wane. The interstitial inflammation seen in affected tissues is a manifestation of the host's attempt to control viral replication, but this response can also contribute to tissue damage. For example, the severe pneumonia in neonatal infection may reflect an exuberant but ineffective inflammatory response in a developing immune system. In the context of laboratory animal medicine, understanding this immunopathogenesis is crucial for interpreting results from vaccine and therapeutic studies. The CIDMTR strain, with its capacity to reinfect immune dams and transmit vertically, provides a robust model for studying immune evasion and the correlates of protective immunity [1].
Diagnostic Approaches for GPCMV: Molecular, Serological, and Histopathological Methods
The accurate diagnosis of guinea pig cytomegalovirus (GPCMV) infection is a multifaceted endeavor that requires a sophisticated integration of molecular, serological, and histopathological methodologies. As a betaherpesvirus with significant utility as a model for congenital human cytomegalovirus (HCMV) infection, GPCMV presents unique diagnostic challenges that demand a rigorous, evidence-based approach. The diagnostic landscape is complicated by the existence of multiple viral strains, the potential for latent and recurrent infections, and the need to differentiate GPCMV from other pathogens that can cause similar clinical presentations in guinea pigs. This section provides an exhaustive analysis of the current diagnostic armamentarium, emphasizing the biological principles underlying each method, their specific applications, and their limitations within the context of veterinary medicine and translational research.
Molecular Diagnostic Methods: Nucleic Acid Detection and Characterization
Molecular diagnostics represent the gold standard for the direct detection and characterization of GPCMV, offering unparalleled sensitivity and specificity. The cornerstone of molecular detection is the polymerase chain reaction (PCR), which can be designed to target conserved regions of the viral genome, such as the DNA polymerase gene or the glycoprotein B (gB) gene. However, the genetic diversity among GPCMV isolates necessitates careful primer design. The reference strain, GPCMV 22122, isolated in 1957, has been the primary comparator for decades. The subsequent isolation and full-genome sequencing of the CIDMTR strain [1, 2] revealed a genome of 232,778 nucleotides, which, while generally well-conserved with the 22122 strain, contains regions of substantial sequence divergence. Critically, the CIDMTR strain possesses novel open reading frames (ORFs), including an additional MHC Class I homolog near the right genome terminus, which are absent in the 22122 strain [1, 2]. This genomic variability has profound implications for diagnostic PCR: assays targeting regions of high variability may fail to detect divergent strains, leading to false-negative results. Therefore, a robust molecular diagnostic strategy must employ either a multi-target PCR approach (e.g., amplifying both conserved and variable genomic regions) or utilize next-generation sequencing (NGS) for comprehensive viral characterization.
Real-time quantitative PCR (qPCR) is the preferred method for viral load quantification, which is critical for monitoring disease progression, assessing the efficacy of antiviral therapies, and understanding the dynamics of congenital transmission. The CIDMTR strain has been demonstrated to be capable of dissemination in immune-compromised guinea pigs and, importantly, of congenital transmission in GPCMV-immune dams previously infected with the salivary gland-adapted 22122 strain [1]. This finding underscores the necessity of strain-specific qPCR assays to differentiate between primary infection and re-infection in vaccine and therapeutic studies. The biological mechanism of viral shedding and dissemination can be tracked molecularly; for instance, the detection of GPCMV DNA in saliva, urine, or blood via qPCR provides a non-invasive or minimally invasive means of monitoring active viral replication. The high sensitivity of qPCR allows for the detection of viral DNA even during latent infection, although the clinical significance of low-level viremia in asymptomatic animals remains an area of active investigation.
For definitive strain identification and epidemiological tracking, whole-genome sequencing (WGS) using platforms such as Illumina and PacBio is indispensable. The sequencing of the CIDMTR strain [1, 2] not only confirmed its taxonomic placement within the Herpesvirinae subfamily but also revealed the presence of strain-specific immune modulation genes. These genes, particularly the MHC Class I homologs, are of paramount interest as they likely mediate viral evasion of the host adaptive immune response. From a diagnostic perspective, the identification of such genes can serve as a molecular marker for strain typing and may predict virulence or transmissibility. Furthermore, NGS-based metagenomics offers the potential to detect GPCMV in clinical samples without a priori knowledge of the infecting strain, making it a powerful tool for investigating outbreaks of undifferentiated illness in guinea pig colonies.
Serological Diagnostic Methods: Humoral Immune Response Profiling
Serological assays are essential for determining prior exposure to GPCMV, assessing vaccine immunogenicity, and conducting seroprevalence studies. The humoral immune response to GPCMV is characterized by the production of virus-specific IgG antibodies, which can be detected using enzyme-linked immunosorbent assays (ELISAs) and virus neutralization (VN) tests. The choice of antigen is critical for serological test performance. Whole-virus lysates, while straightforward to produce, may contain antigens that cross-react with other guinea pig herpesviruses, reducing specificity. Recombinant antigens, such as the glycoprotein B (gB) or the viral MHC Class I homologs, offer superior specificity and allow for the differentiation of antibody responses to different viral strains.
The ELISA is the workhorse of serological diagnostics due to its high throughput, quantitative nature, and relative ease of standardization. In the context of GPCMV, ELISA can be used to measure total IgG titers, and with the use of isotype-specific secondary antibodies, can profile the IgG subclass response, which may correlate with protective immunity. The development of a validated ELISA for GPCMV is analogous to the rigorous validation processes used for other veterinary pathogens. For instance, the establishment of a guinea pig model for vaccine potency testing against Infectious Bovine Rhinotracheitis (IBR) virus demonstrated that ELISA antibody titers in guinea pigs showed an almost perfect agreement with the target species (cattle) when used to predict vaccine efficacy [5]. This principle directly applies to GPCMV: a well-validated ELISA can serve as a surrogate marker for protection in vaccine trials, reducing the need for challenge studies. The World Organisation for Animal Health (WOAH) guidelines for serological test validation emphasize the need for defined reference standards, which for GPCMV should include both positive and negative control sera from animals with known infection status, confirmed by molecular methods.
The virus neutralization (VN) test measures the functional capacity of antibodies to inhibit viral infection in cell culture. This assay is more labor-intensive and slower than ELISA but provides a direct measure of neutralizing antibody titers, which are often considered the primary correlate of protection against herpesviruses. The VN test is particularly relevant for assessing the efficacy of vaccines designed to prevent congenital transmission, as neutralizing antibodies are thought to be critical for blocking transplacental viral passage. The CIDMTR strain, which is capable of re-infecting immune dams [1], provides a stringent test for the breadth of the neutralizing antibody response. A VN test using both the 22122 and CIDMTR strains can determine whether vaccine-induced antibodies are broadly neutralizing or strain-specific. This is analogous to the challenges faced in HCMV vaccine development, where strain-specific neutralizing responses may limit protection against re-infection.
Other serological methods, such as the complement fixation test (CFT) and the Rose Bengal agglutination test (RBT), are less commonly used for GPCMV but are mentioned here for completeness. While CFT has been a mainstay for diagnosing other viral infections, its complexity and lower sensitivity compared to ELISA make it less suitable for routine GPCMV diagnostics. The RBT, a simple and inexpensive agglutination test, is primarily used for bacterial pathogens like Brucella [15] and is not applicable to GPCMV. The selection of a serological method must be guided by the specific diagnostic question: ELISA for high-throughput screening and quantification, VN for functional antibody assessment, and Western blot for confirmatory testing or identification of specific viral protein targets.
Histopathological and Cytopathological Methods: Tissue-Level Diagnosis
Histopathological examination of tissues remains a fundamental diagnostic approach, providing direct visualization of viral cytopathic effects (CPE) and associated inflammatory responses. GPCMV, like all betaherpesviruses, induces characteristic cytomegalic cells, enlarged cells containing both intranuclear and intracytoplasmic inclusion bodies. The intranuclear inclusion is typically large, basophilic or amphophilic, and is surrounded by a clear halo, giving the classic "owl's eye" appearance. Intracytoplasmic inclusions are smaller, basophilic, and often multiple. These inclusions are most readily identified in tissues where viral replication is most active, including the salivary glands (particularly the submandibular and parotid glands), kidneys, liver, lungs, and placenta.
The salivary gland is the primary site of latency and reactivation for GPCMV, and histopathological examination of this tissue is often the most sensitive method for detecting chronic or subclinical infection. In acute infection, the salivary gland acini and ducts show extensive cytomegaly, with inclusion bodies distorting the normal architecture. A mononuclear inflammatory infiltrate, composed primarily of lymphocytes and macrophages, is typically present. In the kidney, GPCMV can cause focal interstitial nephritis, with cytomegalic cells found in the tubular epithelium. The liver may exhibit multifocal necrotizing hepatitis, with inclusion bodies in hepatocytes and Kupffer cells. The placenta is a critical tissue for studying congenital transmission; histopathological examination can reveal villitis, necrosis, and the presence of inclusion bodies in trophoblasts, confirming vertical transmission.
The use of specialized stains can enhance the detection of viral inclusions. Hematoxylin and eosin (H&E) staining is the standard, but periodic acid-Schiff (PAS) stain can highlight the glycoprotein-rich intracytoplasmic inclusions. Immunohistochemistry (IHC) using antibodies directed against GPCMV-specific proteins (e.g., immediate-early or late antigens) provides a quantum leap in diagnostic sensitivity and specificity. IHC allows for the precise localization of viral antigen within specific cell types, even in the absence of visible inclusion bodies. This is particularly valuable in cases of latent infection or when the viral load is low. The development of monoclonal antibodies against the CIDMTR strain-specific proteins [1] could further refine IHC, allowing for the differentiation of infecting strains at the tissue level.
In situ hybridization (ISH) using DNA or RNA probes complementary to GPCMV nucleic acids offers another layer of molecular histopathology. ISH can detect viral DNA or RNA within intact tissue sections, providing spatial context for viral gene expression. This technique is especially useful for studying the dynamics of viral latency and reactivation, as it can differentiate between cells harboring latent viral genomes (detectable by DNA ISH) and those supporting active viral transcription (detectable by RNA ISH). The combination of IHC and ISH on serial sections can provide a comprehensive picture of the host-virus interaction at the cellular level.
Electron microscopy (EM) remains the definitive method for identifying viral particles based on morphology. GPCMV virions exhibit the characteristic herpesvirus morphology: an icosahedral nucleocapsid (approximately 100-110 nm in diameter) surrounded by a tegument layer and a lipid envelope bearing viral glycoprotein spikes. The CIDMTR strain was confirmed to have these morphological characteristics by EM [1]. While EM is not practical for routine clinical diagnosis, it is invaluable for the initial characterization of new isolates and for confirming ambiguous cases where other methods have failed. The ultrastructural examination of infected cells can reveal the assembly pathway of the virus, including the formation of capsids in the nucleus, envelopment at the nuclear membrane, and egress through the cytoplasm.
Integration of Diagnostic Modalities and Clinical Context
The most robust diagnostic approach for GPCMV is a multimodal strategy that integrates molecular, serological, and histopathological findings. No single method is infallible. For example, PCR may be negative in a latently infected animal with no active viral shedding, while serology will be positive. Conversely, in an acutely infected, immunocompromised animal, PCR may be strongly positive before a detectable antibody response has developed. Histopathology provides the definitive link between the presence of the virus and tissue pathology, confirming that GPCMV is the causative agent of observed lesions.
The choice of diagnostic method must also be guided by the clinical context. In a research setting investigating congenital transmission, a combination of qPCR on maternal blood and amniotic fluid, serology to assess pre-existing immunity, and histopathology of the placenta and fetal tissues is essential. For a veterinary practitioner presented with a guinea pig exhibiting sialadenitis (salivary gland inflammation) or unexplained hepatitis, a PCR on a salivary gland biopsy or a buccal swab, coupled with serology, would be the most efficient diagnostic pathway. The recent recognition of GPCMV as a potential cause of disease in pet guinea pigs, paralleling the increasing veterinary interest in this species [4, 8, 14], underscores the need for accessible and validated diagnostic tests.
The emergence of the CIDMTR strain [1, 2] has fundamentally altered the diagnostic landscape. It has demonstrated that re-infection with a heterologous strain is possible even in the presence of pre-existing immunity, a finding with profound implications for vaccine development and diagnostic interpretation. A positive serological test for GPCMV does not guarantee protection against all strains. Therefore, molecular characterization of the infecting strain is becoming increasingly important for both clinical management and epidemiological surveillance. The reference intervals for hematology and biochemistry in guinea pigs [4] are also critical for interpreting histopathological findings, as they provide a baseline for assessing the systemic impact of GPCMV infection.
In conclusion, the diagnostic approach to GPCMV requires a deep understanding of viral biology, host immune response, and the strengths and limitations of each available technique. The integration of molecular, serological, and histopathological methods, guided by the specific clinical or research question, provides the most comprehensive and accurate diagnosis. As new GPCMV strains continue to be identified and characterized, the diagnostic toolkit must evolve in parallel, incorporating advanced genomic and proteomic technologies to stay ahead of this complex and important pathogen.
GPCMV as a Model for Human Cytomegalovirus: Congenital Infection and Re-infection Studies
The study of human cytomegalovirus (HCMV) remains one of the most pressing challenges in congenital infectious disease research, representing the leading infectious cause of sensorineural hearing loss and neurodevelopmental disability in newborns worldwide. The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) have consistently identified congenital HCMV as a priority area for vaccine development, yet despite decades of effort, no licensed vaccine exists. The central obstacle to vaccine advancement lies in the complex biology of HCMV, particularly the phenomenon of re-infection with heterologous viral strains in seropositive women, which can result in vertical transmission and congenital disease even in the presence of pre-conception immunity [1]. This immunological paradox has necessitated the development of an animal model that faithfully recapitulates the nuances of HCMV pathogenesis, transplacental transmission, and the capacity for re-infection. Among the available small animal models, guinea pig cytomegalovirus (GPCMV) has emerged as the most biologically and experimentally relevant system for these investigations, owing to a unique constellation of virological, immunological, and reproductive characteristics that cannot be replicated in murine or other rodent models.
The Unique Suitability of the Guinea Pig Model
The guinea pig (Cavia porcellus) possesses a hemomonochorial placenta that bears striking histological and functional resemblance to the human placenta, a feature that is conspicuously absent in the mouse model. In mice, the placental architecture is labyrinthine and hemotrichorial, with three trophoblast layers interposed between maternal and fetal circulations, creating a barrier that significantly limits the translatability of murine cytomegalovirus (MCMV) studies to human congenital infection. By contrast, the guinea pig placenta, like that of humans, is hemomonochorial, with a single layer of trophoblast cells separating maternal blood from fetal endothelium. This structural homology is not merely anatomical; it underpins the capacity of GPCMV to cross the placental barrier and establish congenital infection in a manner that closely mirrors HCMV transmission dynamics [1]. This placental similarity has been exploited in numerous experimental paradigms, establishing the guinea pig as the only small animal model in which vertical transmission of CMV can be reliably studied following both primary infection and re-infection of the immunocompetent dam.
Furthermore, the relatively long gestation period of the guinea pig (approximately 65–70 days) compared to the mouse (19–21 days) provides an extended window for studying the kinetics of transplacental viral dissemination, fetal organotropism, and the developmental consequences of in utero infection. This gestational timeline more closely approximates the temporal dynamics of human pregnancy, allowing for the investigation of interventions, whether antiviral agents, passive immunization, or vaccine candidates, at various stages of fetal development. The guinea pig model also offers practical advantages, including the relatively large size of fetuses and neonates, which facilitates detailed pathological, virological, and immunological analyses that are technically challenging in murine models [1, 2].
The CIDMTR Breakthrough and Implications for Re-infection Modeling
For decades, the GPCMV field was constrained by the availability of only a single viral strain, the 22122 reference strain, which had been originally isolated in 1957 and serially passaged in salivary glands to maintain virulence [1]. This monoculture situation severely limited the ability to model re-infection, a phenomenon that is now recognized as a critical driver of congenital HCMV transmission in seropositive women. Epidemiological studies have demonstrated that women with pre-existing HCMV immunity can acquire new viral strains from infected children or other contacts, and these re-infections can lead to vertical transmission with consequent fetal damage. To address this gap, the isolation and characterization of the CIDMTR strain represented a seminal advance in the field [1, 2].
The CIDMTR strain was recovered from a naturally infected guinea pig and subjected to comprehensive molecular and biological characterization. Electron microscopy confirmed the typical herpesvirus morphology, while Illumina and PacBio sequencing revealed a genome of 232,778 nucleotides, establishing CIDMTR as a distinct viral entity [2]. Comparative genomic analysis between CIDMTR and the 22122 reference strain demonstrated substantial conservation across the core replicative and structural gene repertoire, but also identified regions of significant sequence divergence that are of profound immunological and experimental importance [1, 2]. Notably, CIDMTR encodes novel open reading frames (ORFs) that are absent in the 22122 genome, including an additional MHC Class I homolog near the right genome terminus [1, 2]. This finding is particularly relevant to modeling HCMV immune evasion, as HCMV employs a sophisticated array of MHC Class I homologs (e.g., UL18, UL142) to subvert natural killer cell surveillance and modulate the host adaptive immune response. The presence of a unique MHC I homolog in CIDMTR suggests that this strain may engage in distinct host–pathogen interactions at the immunological interface, potentially influencing the capacity for re-infection in previously immune hosts.
Experimental Validation of Re-infection in the GPCMV Model
The experimental demonstration of re-infection in the GPCMV model, enabled by the isolation of CIDMTR, represents a landmark achievement with direct translational relevance to human HCMV vaccine development. In a series of carefully designed experiments, female guinea pigs were initially infected with the salivary gland-adapted 22122 strain and allowed to develop robust antiviral immunity, mimicking the natural state of HCMV seropositivity in women of childbearing age. These immune dams were subsequently challenged with the heterologous CIDMTR strain during pregnancy, and the outcomes were evaluated for evidence of re-infection and congenital transmission [1].
The results were unequivocal: CIDMTR was capable of disseminating systemically in 22122-immune dams and, critically, was able to cross the placenta and establish congenital infection in fetuses despite the presence of pre-existing immunity directed against the 22122 strain. This experimental outcome directly parallels the clinical scenario in which HCMV-seropositive women experience re-infection with community-circulating strains and subsequently deliver congenitally infected infants. The demonstration that heterologous re-infection can occur in the GPCMV model, and that such re-infection leads to vertical transmission, provides a robust platform for evaluating vaccine strategies designed to prevent this phenomenon [1]. This is a capability that simply does not exist in the MCMV model, given the fundamental differences in placental structure and the inability of MCMV to efficiently cross the murine placenta.
Genomic Divergence and Immune Evasion Mechanisms
The genomic characterization of the CIDMTR strain has revealed that the degree of sequence divergence between CIDMTR and 22122 is not uniform across the genome. While many regions, particularly those encoding core structural proteins and enzymes involved in DNA replication and packaging, are highly conserved, other regions exhibit substantial nucleotide and amino acid variation [2]. These divergent regions are enriched in ORFs that are predicted to encode proteins involved in immune modulation, including the aforementioned MHC Class I homolog as well as putative chemokine-binding proteins and Fc receptor-like molecules [1, 2]. This genomic architecture mirrors that of HCMV, where the strain-to-strain variability is concentrated in the UL/b’ region and other loci that encode immunoevasins.
From a mechanistic standpoint, the capacity of CIDMTR to establish infection in 22122-immune hosts likely reflects the antigenic differences in these immunomodulatory gene products. The adaptive immune response directed against the 22122 strain, while effective at controlling homologous challenge, may fail to recognize epitopes presented by CIDMTR-encoded proteins that are structurally or antigenically distinct. This antigenic variation at key immune targets, particularly those involved in CD8+ T cell recognition and NK cell modulation, provides a plausible biological basis for re-infection. The GPCMV model thus offers a powerful experimental system for dissecting the precise immunological determinants that govern cross-protection versus susceptibility to heterologous challenge, potentially identifying the viral antigens that must be included in a comprehensive HCMV vaccine to elicit broadly neutralizing immunity [1, 2].
Translational Applications and Vaccine Development
The CIDMTR/22122 two-strain system has immediate and far-reaching implications for the preclinical evaluation of HCMV vaccine candidates. Investigators can now test whether a vaccine derived from the 22122 strain, or a multivalent vaccine incorporating antigens from both strains, can prevent re-infection with CIDMTR in the guinea pig model. This is directly analogous to the clinical challenge of developing an HCMV vaccine that protects against the genetically diverse strains circulating in the human population. The model permits the evaluation of not only viral vectored or subunit vaccines but also passive immunization strategies, such as the administration of hyperimmune globulin or monoclonal antibodies targeting conserved epitopes.
Moreover, the guinea pig model allows for the assessment of vaccine efficacy across multiple endpoints: reduction in maternal viral load, prevention of viremia following heterologous challenge, blockade of placental transmission, and attenuation of fetal disease. The availability of two genetically distinct strains enables sophisticated challenge studies that can distinguish between sterilizing immunity and partial protection, data that are critical for establishing immunological correlates of protection that can guide human clinical trial design [1]. The World Organisation for Animal Health (WOAH) has recognized the role of guinea pig models in the standardization of vaccine potency testing for other pathogens, and the rigorous statistical validation frameworks developed for those applications can be adapted to the CMV field [5].
Comparative Biology and the Broader Context of GPCMV Research
It is important to contextualize the GPCMV congenital infection and re-infection model within the broader landscape of guinea pig research. The species has long served as a model for diverse infectious diseases, from tuberculosis and brucellosis to hemorrhagic fever viruses, and the availability of well-characterized reference strains and immunological reagents continues to expand [3, 4, 12]. The establishment of reference intervals for hematological and biochemical parameters in Dunkin Hartley guinea pigs, including age- and sex-dependent variations, provides essential baseline data for interpreting the physiological effects of CMV infection and the safety profiles of experimental therapeutics [4]. Similarly, the characterization of coagulation parameters in inbred strain 13/N guinea pigs, used extensively in hemorrhagic fever research, demonstrates the depth of physiological characterization available for this species [3].
The immunological toolbox for guinea pig research, while less extensive than that for mice, has grown considerably. Investigators now have access to species-specific reagents for flow cytometry, cytokine quantitation, and histopathology, enabling detailed dissection of the host response to GPCMV infection and re-infection. The cerebellum stereological studies and cranial morphometric analyses, while seemingly unrelated, underscore the breadth of anatomical and physiological knowledge that supports the guinea pig as a well-characterized experimental subject [8, 14]. This comprehensive understanding of guinea pig biology enhances the interpretability and translational relevance of GPCMV studies.
Future Directions and Unresolved Questions
Despite the remarkable progress enabled by the CIDMTR isolate, several important questions remain. The precise molecular determinants that allow CIDMTR to evade 22122-induced immunity have not been fully elucidated. Systematic gene-by-gene replacement studies, in which individual CIDMTR ORFs are introduced into a 22122 background (or vice versa), could identify the specific viral proteins responsible for the re-infection phenotype. The identification of these determinants could inform the design of cross-protective vaccine antigens.
Additionally, the relative contributions of humoral and cellular immunity to protection against re-infection in the GPCMV model require careful dissection. While neutralizing antibodies are undoubtedly important, the role of CD8+ T cells directed against conserved versus strain-specific epitopes warrants investigation. Adoptive transfer experiments, using defined T cell populations from 22122-immune donors, could clarify the cellular correlates of protection. The two-strain system also provides an opportunity to study the dynamics of viral quasispecies evolution during re-infection, particularly in the context of immune pressure, as well as the potential for recombination between strains during co-infection, a phenomenon that could generate novel viral variants with unpredictable pathogenic potential.
Finally, the GPCMV model must be leveraged to test next-generation vaccine platforms, including mRNA-based vaccines, virus-like particle vaccines, and vectored approaches targeting the conserved glycoprotein complexes (gB, gH/gL/gO, and the pentameric complex) that are the focus of HCMV vaccine development. The ability to evaluate these platforms against both primary infection and heterologous re-infection in the guinea pig model provides a critical, high-fidelity filter before advancing to human clinical trials. The sustained investment in this model, supported by the molecular characterization of the CIDMTR strain and the growing body of guinea pig reference data, positions GPCMV as an indispensable tool in the global effort to eliminate congenital CMV disease [1-4].
Prevention, Treatment, and Biosecurity Considerations for GPCMV in Laboratory and Pet Guinea Pigs
The management of guinea pig cytomegalovirus (GPCMV) in both laboratory and pet settings presents a unique set of challenges that diverge substantially from those encountered with other viral pathogens of Cavia porcellus. Unlike acute, self-limiting infections that permit straightforward eradication strategies, GPCMV establishes lifelong latency with periodic reactivation, a hallmark of the Betaherpesvirinae subfamily to which it belongs [1, 2]. This biological reality fundamentally shapes all preventive, therapeutic, and biosecurity interventions. The recent isolation and genomic characterization of the CIDMTR strain, which demonstrates the capacity for superinfection and congenital transmission even in previously immune dams, underscores the inadequacy of relying solely on natural immunity as a protective strategy and mandates a more rigorous, multi-layered approach [1, 2]. Consequently, the prevention and control of GPCMV cannot be reduced to a simple vaccination protocol or a single biosecurity measure; rather, it requires an integrated framework addressing viral latency, environmental stability, diagnostic surveillance, and the distinct risk profiles of laboratory colonies versus individual pet animals.
Biological Basis for Prevention Strategies: Latency, Re-Infection, and Vertical Transmission
The foundation of any effective prevention program must rest upon a thorough understanding of GPCMV's unique pathogenic mechanisms. Following primary infection, which is often subclinical in immunocompetent animals, the virus establishes a latent state within myeloid progenitor cells and other tissues, persisting for the lifetime of the host. This latency is punctuated by episodes of reactivation, which may be triggered by physiological stress, immunosuppression, pregnancy, or concurrent disease [1]. The critical insight provided by the CIDMTR strain research is that pre-existing immunity from prior infection with one GPCMV strain (e.g., the 22122 reference strain) does not confer sterile immunity against heterologous reinfection. In the study by Schleiss et al., GPCMV-immune dams were successfully superinfected with the CIDMTR strain, which then underwent vertical transmission to offspring [1]. This finding has profound implications for prevention: if naturally acquired immunity is insufficient to block reinfection and congenital transmission, then any vaccine strategy must aim for a level of immune response that exceeds that of natural infection, or alternatively, must target conserved epitopes across circulating strains. The genomic divergence between the 22122 and CIDMTR strains, including the presence of strain-specific open reading frames encoding putative immune modulation gene products (e.g., an additional MHC Class I homolog near the right genome terminus), may explain this capacity for immune evasion [2]. Prevention programs, therefore, cannot assume that a single exposure or a monovalent vaccine will provide lifelong protection.
In laboratory settings, the implications are particularly stark. Breeding colonies are at high risk for endemic GPCMV circulation, as latent dams can reactivate virus during gestation and transmit it to pups, perpetuating a cycle of infection that is difficult to break [1]. Serological monitoring for GPCMV antibodies should be a cornerstone of colony health surveillance, yet the existence of strain-specific immune responses complicates interpretation. A dam seropositive for the 22122 strain may still be susceptible to the CIDMTR strain, and standard serological assays may not differentiate between these infections. This necessitates molecular diagnostic approaches, such as PCR targeting conserved genomic regions, to confirm the absence of active viral shedding [1, 2]. For specific-pathogen-free (SPF) colonies, the introduction of any new animal, even one that is seropositive, represents a potential biosecurity breach, given the possibility of latent virus reactivation under the stress of transportation and acclimation.
Vaccination: Current Status and Future Directions
At present, there is no licensed commercial vaccine for GPCMV in guinea pigs. However, the guinea pig model has been extensively utilized for the development and potency testing of vaccines against other pathogens, including bovine herpesvirus-1 (BoHV-1) and rabies virus, demonstrating the species' utility in vaccine research [5, 6]. The validated BoHV-1 potency model in guinea pigs, which showed a dose-response relationship and the ability to discriminate between vaccines of differing antigen content with excellent repeatability (CV ≤ 20%), provides a methodological framework that could be adapted for GPCMV vaccine development [5]. Similarly, the guinea pig potency test historically used for rabies vaccines in Japan, which involved challenge protection assays, demonstrates the regulatory acceptability of this species for vaccine evaluation [6].
For GPCMV specifically, vaccine development faces the hurdle of achieving immunity that surpasses natural infection. The CIDMTR strain's ability to infect immune dams suggests that a successful vaccine must elicit robust mucosal and systemic immunity, likely including both neutralizing antibodies and cell-mediated responses targeting conserved viral proteins. The identification of strain-specific ORFs in CIDMTR, particularly those encoding MHC Class I homologs that may interfere with antigen presentation, highlights the need for a multivalent or chimeric vaccine approach [1, 2]. Adjuvant selection will be critical; recent work with saturated α-olefin oligomer (SAOL)-based water-in-oil nanoemulsions has demonstrated immunoenhancing effects in guinea pigs, with no observed toxicity or pathological changes upon injection [16]. Such sustained-release formulations could provide the prolonged antigen exposure necessary to induce durable immune memory against a latent virus. However, until such vaccines are developed and evaluated in controlled trials, prevention must rely on biosecurity management and, where necessary, antiviral or supportive interventions.
Therapeutic Interventions: Antiviral and Supportive Care
Treatment options for GPCMV infections are primarily extrapolated from human cytomegalovirus (HCMV) management, as GPCMV shares similar biological properties, including susceptibility to certain antiviral agents. Ganciclovir and its oral prodrug valganciclovir, which inhibit viral DNA polymerase by acting as nucleoside analogues, have been used experimentally in guinea pig models. Cidofovir, a nucleotide analogue, offers an alternative mechanism of action and may be useful in cases of ganciclovir resistance. However, these drugs carry significant nephrotoxicity and bone marrow suppression risks, and their use in pet guinea pigs is limited by a lack of pharmacokinetic data for the species, the potential for adverse effects, and the high cost of treatment. Furthermore, the establishment of latency means that antiviral therapy can suppress active replication but cannot eradicate the virus from the host, necessitating prolonged or repeated courses of therapy for recurrent disease.
For laboratory guinea pigs, the decision to treat must be weighed against the risk of drug-induced physiological changes that could confound research outcomes. The establishment of hematologic and biochemical reference intervals for Dunkin Hartley guinea pigs, including age- and sex-associated differences, provides a critical baseline for monitoring potential drug toxicities during antiviral therapy [4]. For example, ganciclovir-induced myelosuppression might manifest as decreased white blood cell counts, particularly lymphocytes, which normally decrease with age in this strain [4]. Similarly, monitoring renal function through blood urea nitrogen and creatinine, parameters that increase with age, is essential when using nephrotoxic agents [4]. Coagulation parameters, including prothrombin time, activated partial thromboplastin time, and fibrinogen, have been established for strain 13/N guinea pigs, providing a framework for detecting hemorrhagic complications that may arise from severe disseminated GPCMV infection or drug toxicity [3].
In the absence of specific antiviral therapy for many clinical cases, supportive care remains the cornerstone of management. This includes maintaining hydration, nutritional support via syringe feeding or nasogastric intubation, and management of secondary bacterial infections. The risk of bacterial complications is particularly relevant given that GPCMV-induced immunosuppression, especially during pregnancy or neonatal life, can predispose to opportunistic infections. Importantly, clinicians must remain vigilant for concurrent diseases that may mimic or exacerbate GPCMV infection. For instance, gastrointestinal disease presenting with gastric dilatation volvulus (GDV) has been documented in guinea pigs and could be confused with the abdominal discomfort sometimes associated with viral disease [10]. Similarly, dermatological conditions such as sporotrichosis, now documented in guinea pigs and carrying zoonotic potential, require differentiation from viral-associated skin lesions [7]. The use of point-of-care lactate measurement, for which reference intervals in guinea pigs are 0.49–1.83 mmol/L (iSTAT) to 0.60–2.2 mmol/L (Lactate Plus), can aid in assessing disease severity and guiding fluid therapy decisions [9].
Biosecurity Considerations in Laboratory Colonies
The control of GPCMV in laboratory colonies demands a comprehensive biosecurity program that addresses introduction, containment, and monitoring. As noted, the CIDMTR strain was capable of dissemination in immune-compromised guinea pigs, indicating that even animals with prior exposure are not fully protected [1]. Therefore, the gold standard for SPF colonies is the exclusion of GPCMV entirely. This requires that all incoming animals originate from GPCMV-free sources, undergo a minimum 30-day quarantine period, and be tested for GPCMV DNA by PCR of blood, saliva, or feces before introduction to the main colony. Given the latency of the virus, a single negative test is insufficient; serial testing over the quarantine period, coupled with serological screening, provides greater confidence in infection-free status.
Within the colony, strict barrier precautions are necessary. The virus is shed in saliva, urine, and genital secretions, so procedures that prevent fomite transmission, including dedicated equipment per room or cage, frequent hand hygiene, and the use of personal protective equipment (PPE) such as gloves, gowns, and shoe covers, are essential. The shared use of equipment between cages or rooms in veterinary clinics has been implicated in the nosocomial spread of other multidrug-resistant pathogens in guinea pigs and other small mammals [11]. In a study of OXA-48 carbapenemase-producing Enterobacteriaceae, one guinea pig among 43 tested (2.3%) was found to harbor the resistance gene, and clonal analysis suggested nosocomial transmission within a university veterinary clinic [11]. While this study addressed bacterial resistance, the same principle applies to viral pathogens: once GPCMV is introduced, the potential for iatrogenic spread through contaminated instruments, anesthesia circuits, or shared housing is substantial. Therefore, dedicated equipment for each isolator or room, rigorous disinfection protocols (including the use of disinfectants with proven activity against enveloped viruses, such as accelerated hydrogen peroxide or sodium hypochlorite), and meticulous hand hygiene are non-negotiable.
The management of breeding colonies presents additional challenges. Pregnancy is a well-known trigger for GPCMV reactivation, and congenitally infected pups may shed virus at high titers, perpetuating infection within the colony. The CIDMTR strain's documented capacity for congenital transmission in immune dams indicates that even a previously exposed breeder population is at risk for producing infected offspring [1]. Consequently, a test-and-cull strategy may be necessary for eradication in breeding facilities, with periodic screening of all animals and immediate removal of seropositive individuals. Alternatively, strict separate housing of breeding pairs from the main colony, with dedicated barrier protocols, can limit the spread of infection if it occurs.
Biosecurity in Pet Guinea Pig Populations
For pet guinea pigs, biosecurity considerations are distinct. The risk of GPCMV introduction into a household is lower than in high-density laboratory colonies, but it is not negligible. New guinea pigs should be quarantined for at least 2–4 weeks before introduction to resident animals, and ideally tested for GPCMV if resources permit. Clinical signs of primary infection in immunocompetent adult pet guinea pigs are often mild or subclinical, but stress, such as from shipping, concurrent illness, or environmental change, can precipitate reactivation and shedding. Owners should be counseled that GPCMV is species-specific; there is no known zoonotic transmission to humans, as the virus is adapted to the guinea pig host and does not infect human cells. However, as with all veterinary pathogens, standard hygiene practices, including hand washing after handling animals or cleaning cages, are prudent, especially for immunocompromised individuals.
The association between GPCMV and reproductive failure is of particular concern for hobby breeders. Stillbirth, neonatal death, and runting are potential outcomes of congenital infection, and a history of such events should prompt diagnostic investigation for GPCMV [1]. Breeding animals that have experienced such outcomes should be tested, and if positive, removed from the breeding program to prevent further vertical transmission. The CIDMTR strain's ability to infect previously immune dams suggests that natural immunity acquired from a prior infection is an unreliable basis for breeding decisions [1]. Veterinarians advising breeders must emphasize that a prior healthy litter does not guarantee protection against a new strain or reactivation of latent virus under the stress of successive pregnancies.
Regulatory and Reporting Considerations
At present, GPCMV is not a reportable disease to the World Organisation for Animal Health (WOAH) or national veterinary authorities, and it does not fall under the purview of the Centers for Disease Control and Prevention (CDC) for zoonotic control. However, for laboratory animal facilities that operate under strict SPF standards, GPCMV status is a critical parameter that influences research validity, particularly in studies involving immunomodulation, vaccine testing, or reproductive biology. The WHO has recognized the guinea pig as a valuable model for evaluating vaccine potency and safety, as evidenced by its historical use in rabies vaccine testing [6]. For facilities housing guinea pigs, internal documentation of GPCMV status, whether positive or negative, should be maintained, and this status should be transparently communicated when animals are transferred to other institutions.
Future Directions and Research Needs
Significant knowledge gaps impede the development of evidence-based prevention and treatment protocols. The epidemiology of GPCMV in pet guinea pig populations remains poorly characterized; prevalence surveys using molecular methods are needed to understand the true burden of infection. The development of rapid, point-of-care diagnostic assays would facilitate screening in veterinary practice. Furthermore, research into the viral determinants of latency and reactivation could identify novel therapeutic targets, potentially enabling the development of drugs that prevent reactivation rather than simply suppressing active replication. The role of stress and co-infections in triggering reactivation also requires systematic investigation, as management modifications (e.g., environmental enrichment, reducing transport stress) might reduce viral shedding and transmission. Finally, the potential for GPCMV to serve as a model for understanding congenital HCMV infection in humans, given that both viruses establish latency and can cross the placenta to cause fetal disease, underscores the translational importance of continued research into prevention and treatment in this species [1].
References
[1] Schleiss M, McAllister S, Armién A, Hernandez-Alvarado N, Fernández-Alarcón C, Zabeli JC, et al.. Molecular and Biological Characterization of a New Isolate of Guinea Pig Cytomegalovirus. Viruses. 2014. DOI: https://doi.org/10.3390/v6020448
[2] Schleiss M, Hernandez-Alvarado N, Ramaraj T, Crow J. Genome Sequence of a Novel, Newly Identified Isolate of Guinea Pig Cytomegalovirus, the CIDMTR Strain. Genome Announcements. 2013. DOI: https://doi.org/10.1128/genomeA.01052-13
[3] Condrey JA, Flietstra TD, Nestor KM, Schlosser E, Coleman-McCray J, Genzer S, et al.. Prothrombin Time, Activated Partial Thromboplastin Time, and Fibrinogen Reference Intervals for Inbred Strain 13/N Guinea Pigs (Cavia porcellus) and Validation of Low Volume Sample Analysis. Microorganisms. 2020. DOI: https://doi.org/10.3390/microorganisms8081127
[4] Spittler AP, Afzali MF, Bork S, Burton L, Radakovich LB, Seebart C, et al.. Age- and sex-associated differences in hematology and biochemistry parameters of Dunkin Hartley guinea pigs (Cavia porcellus). PLoS ONE. 2021. DOI: https://doi.org/10.1371/journal.pone.0253794
[5] Parreño V, López MV, Rodriguez D, Vena M, Izuel M, Filippi J, et al.. Development and statistical validation of a guinea pig model for vaccine potency testing against Infectious Bovine Rhinothracheitis (IBR) virus. Vaccine. 2010. DOI: https://doi.org/10.1016/j.vaccine.2010.01.035
[6] Gamoh K, Shimazaki Y, Senda M, Makie H, Itoh O, Muramatsu M, et al.. Establishment of a potency test by ELISA for a rabies vaccine for animal use in Japan.. Journal of Veterinary Medical Science. 2003. DOI: https://doi.org/10.1292/JVMS.65.685
[7] Júnior FRP, Moreira AC, Medeiros NO, Carmo M, Lima M. Sporotrichosis in guinea pig (Cavia porcellus) - case report]. Arquivo Brasileiro de Medicina Veterinária e Zootecnia. 2024. DOI: https://doi.org/10.1590/1678-4162-13132
[8] Silva Md, Sadeghinezhad J, Nyengaard J, Asl MA, Saeidi A, Sordi ND, et al.. Design‐based stereological study of the guinea‐pig (Cavia porcellus) cerebellum. Journal of Anatomy. 2021. DOI: https://doi.org/10.1111/joa.13434
[9] Levy I, Spittler AP, Santangelo K, Sadar MJ. Comparison of two point of care lactate instruments in guinea pigs (Cavia porcellus). Journal of Exotic Pet Medicine. 2023. DOI: https://doi.org/10.1053/j.jepm.2023.03.002
[10] Huynh M, Pignon C. Gastrointestinal Disease in Exotic Small Mammals. Journal of Exotic Pet Medicine. 2013. DOI: https://doi.org/10.1053/j.jepm.2013.05.004
[11] Pulss S, Stolle I, Stamm I, Leidner U, Heydel C, Semmler T, et al.. Multispecies and Clonal Dissemination of OXA-48 Carbapenemase in Enterobacteriaceae From Companion Animals in Germany, 2009, 2016. Frontiers in Microbiology. 2018. DOI: https://doi.org/10.3389/fmicb.2018.01265
[12] Byrne A, Allen A, O'Brien D, Miller MA. Editorial: Bovine Tuberculosis, International Perspectives on Epidemiology and Management. Frontiers in Veterinary Science. 2019. DOI: https://doi.org/10.3389/fvets.2019.00202
[13] Saunders R. Blackwell's Five Minute Veterinary Consult: Small Mammal. Journal of Small Animal Practice. 2012. DOI: https://doi.org/10.1111/J.1748-5827.2012.01210.X
[14] Yalin EE, Szara T, Günay E, Pešić A, Manuta N, Güzel B, et al.. Sexual Shape Variation and Allometric Effects in Guinea Pig (Cavia porcellus) Skulls. Animals. 2025. DOI: https://doi.org/10.3390/ani15233453
[15] Vicente AF, Troupin C, Grayo S, Ellis-Bangoura I, Doukouré B, Camara A, et al.. Comparison of serological tools for reliable diagnosis of brucellosis circulation in the West-African context. BMC Veterinary Research. 2026. DOI: https://doi.org/10.1186/s12917-025-05183-z
[16] Ye J, Lu X, Chen C, Zhou H, Zhou Y, Wu L, et al.. Saturated α‑Olefin Oligomer as a W/O Nanoemulsion for Veterinary Immune Adjuvants Based on Crude Oil to Chemicals Technology. ACS Omega. 2025. DOI: https://doi.org/10.1021/acsomega.5c03762